Major assets in Radiobiology
Benefiting from the installation of an advanced radiotherapy technology park and a laboratory for radiobiology research on the same campus, this Program aims to develop original and competitive translational research in the field of oncologic radiotherapy.
The implementation of this Program relies on an already well-structured network, the close relationship between the ICM and the IRCM having fostered close links between clinicians and researchers working on this theme.
The Coordination of this Program is provided by a clinician and a researcher working together; Pr David Azria, Coordinator of the Oncology radiotherapy Division of the ICM, and Dr. Muriel Brengues, PhD, Research Scientist IRCM
This collaboration allows for the combining of major clinical and scientific advances in the field of anti-tumour therapies via antibodies and their association with ionising radiations.
New strategies for personalised radiotherapy
Effective external radiation therapy requires the homogeneous delivery of an adequate total dose to the targeted tumor tissue. In addition and in many tumor indications, combined treatment of ionizing radiation and drugs has proven its superiority compared to radiation alone in terms of locoregional control. Dose delivery with or without systemic molecules may however be hindered by the tolerance of surrounding normal tissues in the irradiated volume. While the potential side effects of radiation therapy are numerous and well-described, it is currently impossible to predict the extent of such effects for a given individual patient. This was one of the bases of development of predictive assays to identify patients harboring an intrinsically greater risk to develop severe late normal-tissue toxicity in the era of combined external radiation and medical strategies.
The goal of this program is to improve knowledge of radiobiological parameters predictive of efficiency and tolerance to ionizing radiation in order to develop new strategies in personalised radiotherapy. Strategic directions for the program are focussed on two main objectives:
Axis 1: Preventing, predicting, and curing side effects after external radiotherapy
Axis 2: Targeted radionuclide therapy by investigating the relationship between delivered dose and biologival effects in tumoursand normal tissues